miRNA-708 functions as a tumour suppressor in hepatocellular carcinoma by targeting SMAD3

Li,Qi; Li,Sheng; Wu,Yaolu; Gao,Feng

doi:10.3892/ol.2017.6429

miRNA-708 functions as a tumour suppressor in hepatocellular carcinoma by targeting SMAD3

Authors:
- Qi Li
- Sheng Li
- Yaolu Wu
- Feng Gao
View Affiliations

Affiliations: Department of Hepatobiliary Surgery, Yan'an City People's Hospital, Yanan, Shaanxi 716000, P.R. China, The Second Department of General Surgery, Yulin Second Hospital, Yulin, Shaanxi 719000, P.R. China, Department of General Surgery, The Affiliated Hospital of Yan'an University, Yanan, Shaanxi 716000, P.R. China, Department of Hepatobiliary Surgery, The Affiliated Hospital of Yan'an University, Yanan, Shaanxi 716000, P.R. China
Published online on: June 20, 2017 https://doi.org/10.3892/ol.2017.6429
Pages: 2552-2558

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Hepatocellular carcinoma (HCC) is the most frequent subtype of primary liver cancer and the third most common cause of cancer‑associated mortality worldwide. Previous studies have reported that microRNAs (miRNAs) serve key roles in the carcinogenesis and progression of HCC by regulating gene expression. The present study investigated the expression patterns, biological roles and underlying mechanisms of miRNA‑708 (miR‑708) in HCC. The expression levels of miR‑708 in HCC tissue samples and cell lines were examined. Cell proliferation, migration and invasion assays were used to evaluate the effect of miR‑708 on HCC cells. In addition, bioinformatic and western blotting analyses, and dual luciferase reporter assays were performed to investigate the direct gene target of miR‑708. The results of the present study demonstrated that miR‑708 expression was significantly decreased in HCC tissue samples and cell lines. In addition, the expression level of miR‑708 was associated with increased HCC tumour stage. Furthermore, ectopic expression of miR‑708 suppressed HCC cell proliferation, migration and invasion. The results of the present study also indicated that miR‑708 targets SMAD family member 3 directly in vitro. The results of the present study indicated that miR‑708 may be a novel target for future HCC therapy.

View Figures

View References

1	Liu H, Li W, Chen C, Pei Y and Long X: MiR-335 acts as a potential tumor suppressor miRNA via downregulating ROCK1 expression in hepatocellular carcinoma. Tumour Biol. 36:6313–6319. 2015. View Article : Google Scholar : PubMed/NCBI
2	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
3	Huitzil-Melendez FD, Capanu M, O'Reilly EM, Duffy A, Gansukh B, Saltz LL and Abou-Alfa GK: Advanced hepatocellular carcinoma: Which staging systems best predict prognosis? J Clin Oncol. 28:2889–2895. 2010. View Article : Google Scholar : PubMed/NCBI
4	Vertemati M, Moscheni C, Petrella D, Lamperti L, Cossa M, Gambacorta M, Goffredi M and Vizzotto L: Morphometric analysis of hepatocellular nodular lesions in HCV cirrhosis. Pathol Res Pract. 208:240–244. 2012. View Article : Google Scholar : PubMed/NCBI
5	Liang T, Chen EQ and Tang H: Hepatitis B virus gene mutations and hepatocarcinogenesis. Asian Pac J Cancer Prev. 14:4509–4513. 2013. View Article : Google Scholar : PubMed/NCBI
6	Gao J, Xie L, Yang WS, Zhang W, Gao S, Wang J and Xiang YB: Risk factors of hepatocellular carcinoma-current status and perspectives. Asian Pac J Cancer Prev. 13:743–752. 2012. View Article : Google Scholar : PubMed/NCBI
7	Yang LY, Fang F, Ou DP, Wu W, Zeng ZJ and Wu F: Solitary large hepatocellular carcinoma: A specific subtype of hepatocellular carcinoma with good outcome after hepatic resection. Ann Surg. 249:118–123. 2009. View Article : Google Scholar : PubMed/NCBI
8	El-Serag HB and Rudolph KL: Hepatocellular carcinoma: Epidemiology and molecular carcinogenesis. Gastroenterology. 132:2557–2576. 2007. View Article : Google Scholar : PubMed/NCBI
9	Furuta M, Kozaki KI, Tanaka S, Arii S, Imoto I and Inazawa J: miR-124 and miR-203 are epigenetically silenced tumor-suppressive microRNAs in hepatocellular carcinoma. Carcinogenesis. 31:766–776. 2010. View Article : Google Scholar : PubMed/NCBI
10	Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell. 116:281–297. 2004. View Article : Google Scholar : PubMed/NCBI
11	Iwakawa HO and Tomari Y: Molecular insights into microRNA-mediated translational repression in plants. Mol Cell. 52:591–601. 2013. View Article : Google Scholar : PubMed/NCBI
12	Engels BM and Hutvagner G: Principles and effects of microRNA-mediated post-transcriptional gene regulation. Oncogene. 25:6163–6169. 2006. View Article : Google Scholar : PubMed/NCBI
13	Niyazi M, Zehentmayr F, Niemöller OM, Eigenbrod S, Kretzschmar H, Schulze-Osthoff K, Tonn JC, Atkinson M, Mörtl S and Belka C: MiRNA expression patterns predict survival in glioblastoma. Radiat Oncol. 6:1532011. View Article : Google Scholar : PubMed/NCBI
14	Chen G, Lu L, Liu C, Shan L and Yuan D: MicroRNA-377 suppresses cell proliferation and invasion by inhibiting TIAM1 expression in hepatocellular carcinoma. PLoS One. 10:e01177142015. View Article : Google Scholar : PubMed/NCBI
15	Tahara H, Kay MA, Yasui W and Tahara E: MicroRNAs in Cancer: The 22nd Hiroshima Cancer Seminar/the 4th Japanese Association for RNA Interference Joint International Symposium, 30 August 2012, Grand Prince Hotel Hiroshima. Jpn J Clin Oncol. 43:579–582. 2013. View Article : Google Scholar : PubMed/NCBI
16	Yates LA, Norbury CJ and Gilbert RJ: The long and short of microRNA. Cell. 153:516–519. 2013. View Article : Google Scholar : PubMed/NCBI
17	Zhang W, Liu K, Liu S, Ji B, Wang Y and Liu Y: MicroRNA-133a functions as a tumor suppressor by targeting IGF-1R in hepatocellular carcinoma. Tumour Biol. 36:9779–9788. 2015. View Article : Google Scholar : PubMed/NCBI
18	Chen X, Bo L, Zhao X and Chen Q: MicroRNA-133a inhibits cell proliferation, colony formation ability, migration and invasion by targeting matrix metallopeptidase 9 in hepatocellular carcinoma. Mol Med Rep. 11:3900–3907. 2015.PubMed/NCBI
19	Li D, Liu X, Lin L, Hou J, Li N, Wang C, Wang P, Zhang Q, Zhang P, Zhou W, et al: MicroRNA-99a inhibits hepatocellular carcinoma growth and correlates with prognosis of patients with hepatocellular carcinoma. J Biol Chem. 286:36677–36685. 2011. View Article : Google Scholar : PubMed/NCBI
20	Morishita A and Masaki T: miRNA in hepatocellular carcinoma. Hepatol Res. 45:128–141. 2015. View Article : Google Scholar : PubMed/NCBI
21	Imbeaud S, Ladeiro Y and Zucman-Rossi J: Identification of novel oncogenes and tumor suppressors in hepatocellular carcinoma. Semin Liver Dis. 30:75–86. 2010. View Article : Google Scholar : PubMed/NCBI
22	Saini S, Yamamura S, Majid S, Shahryari V, Hirata H, Tanaka Y and Dahiya R: MicroRNA-708 induces apoptosis and suppresses tumorigenicity in renal cancer cells. Cancer Res. 71:6208–6219. 2011. View Article : Google Scholar : PubMed/NCBI
23	Jang JS, Jeon HS, Sun Z, Aubry MC, Tang H, Park CH, Rakhshan F, Schultz DA, Kolbert CP and Lupu R: Increased miR-708 expression in NSCLC and its association with poor survival in lung adenocarcinoma from never smokers. Clin Cancer Res. 18:3658–3667. 2012. View Article : Google Scholar : PubMed/NCBI
24	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
25	Tian F, Byfield S DaCosta, Parks WT, Yoo S, Felici A, Tang B, Piek E, Wakefield LM and Roberts AB: Reduction in Smad2/3 signaling enhances tumorigenesis but suppresses metastasis of breast cancer cell lines. Cancer Res. 63:8284–8292. 2003.PubMed/NCBI
26	Zavadil J and Böttinger EP: TGF-beta and epithelial-to-mesenchymal transitions. Oncogene. 24:5764–5774. 2005. View Article : Google Scholar : PubMed/NCBI
27	Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S, Shimizu M, Rattan S, Bullrich F, Negrini M and Croce CM: Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA. 101:pp. 2999–3004. 2004; View Article : Google Scholar : PubMed/NCBI
28	Bartel DP: MicroRNAs: Target recognition and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
29	Baek D, Villén J, Shin C, Camargo FD, Gygi SP and Bartel DP: The impact of microRNAs on protein output. Nature. 455:64–71. 2008. View Article : Google Scholar : PubMed/NCBI
30	Selbach M, Schwanhäusser B, Thierfelder N, Fang Z, Khanin R and Rajewsky N: Widespread changes in protein synthesis induced by microRNAs. Nature. 455:58–63. 2008. View Article : Google Scholar : PubMed/NCBI
31	Wang Y, Lu Z, Li Y, Ji D, Zhang P, Liu Q and Yao Y: miR-143 inhibits proliferation and invasion of hepatocellular carcinoma cells via down-regulation of TLR2 expression. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 30:1076–1079. 2014.(In Chinese). PubMed/NCBI
32	Yang XW, Zhang LJ, Huang XH, Chen LZ, Su Q, Zeng WT, Li W and Wang Q: miR-145 suppresses cell invasion in hepatocellular carcinoma cells: miR-145 targets ADAM17. Hepatol Res. 44:551–559. 2014. View Article : Google Scholar : PubMed/NCBI
33	Guo P, Lan J, Ge J, Nie Q, Mao Q and Qiu Y: miR-708 acts as a tumor suppressor in human glioblastoma cells. Oncol Rep. 30:870–876. 2013.PubMed/NCBI
34	Song T, Zhang X, Zhang L, Dong J, Cai W, Gao J and Hong B: miR-708 promotes the development of bladder carcinoma via direct repression of Caspase-2. J Cancer Res Clin Oncol. 139:1189–1198. 2013. View Article : Google Scholar : PubMed/NCBI
35	Li X, Li D, Zhuang Y, Shi Q, Wei W and Ju X: Overexpression of miR-708 and its targets in the childhood common precursor B-cell ALL. Pediatr Blood Cancer. 60:2060–2067. 2013. View Article : Google Scholar : PubMed/NCBI
36	Saini S, Majid S, Shahryari V, Arora S, Yamamura S, Chang I, Zaman MS, Deng G, Tanaka Y and Dahiya R: miRNA-708 control of CD44(+) prostate cancer-initiating cells. Cancer Res. 72:3618–3630. 2012. View Article : Google Scholar : PubMed/NCBI
37	Li G, Yang F, Xu H, Yue Z, Fang X and Liu J: MicroRNA-708 is downregulated in hepatocellular carcinoma and suppresses tumor invasion and migration. Biomed Pharmacother. 73:154–159. 2015. View Article : Google Scholar : PubMed/NCBI
38	Kaminska B, Wesolowska A and Danilkiewicz M: TGF beta signalling and its role in tumour pathogenesis. Acta Biochim Pol. 52:329–337. 2005.PubMed/NCBI
39	Massagué J: TGFbeta in Cancer. Cell. 134:215–230. 2008. View Article : Google Scholar : PubMed/NCBI
40	Yang YA, Zhang GM, Feigenbaum L and Zhang YE: Smad3 reduces susceptibility to hepatocarcinoma by sensitizing hepatocytes to apoptosis through downregulation of Bcl-2. Cancer Cell. 9:445–457. 2006. View Article : Google Scholar : PubMed/NCBI
41	Kim SH, Ahn S and Park CK: Smad3 and its phosphoisoforms are prognostic predictors of hepatocellular carcinoma after curative hepatectomy. Hepatobiliary Pancreat Dis Int. 11:51–59. 2012. View Article : Google Scholar : PubMed/NCBI
42	Zhao W, Zou J, Wang B, Fan P, Mao J, Li J, Liu H, Xiao J, Ma W, Wang M, et al: microRNA-140 suppresses the migration and invasion of colorectal cancer cells through targeting Smad3. Zhonghua Zhong Liu Za Zhi. 36:739–745. 2014.(In Chinese). PubMed/NCBI
43	Liu C, Cheng H, Shi S, Cui X, Yang J, Chen L, Cen P, Cai X, Lu Y, Wu C, et al: MicroRNA-34b inhibits pancreatic cancer metastasis through repressing Smad3. Curr Mol Med. 13:467–478. 2013. View Article : Google Scholar : PubMed/NCBI
44	Yang Y, Liu L, Cai J, Wu J, Guan H, Zhu X, Yuan J, Chen S and Li M: Targeting Smad2 and Smad3 by miR-136 suppresses metastasis-associated traits of lung adenocarcinoma cells. Oncol Res. 21:345–352. 2013. View Article : Google Scholar : PubMed/NCBI
45	Huang H, Sun P, Lei Z, Li M, Wang Y, Zhang HT and Liu J: miR-145 inhibits invasion and metastasis by directly targeting Smad3 in nasopharyngeal cancer. Tumour Biol. 36:4123–4131. 2015. View Article : Google Scholar : PubMed/NCBI